Baylor College of Medicine

A Randomized Controlled Trial of Exenatide as an Adjunct to Nicotine Patch for Smoking Cessation and Prevention of Post-Cessation Weight Gain (H-51389)



The purpose of this research study is to investigate a potential treatment for quitting smoking and preventing post-quit weight gain. This study will involve administration of exenatide (Bydureon), which is approved by the Food and Drug Administration (FDA) for the treatment of diabetes but not approved for treating nicotine addiction or weight maintenance. Because of this, exenatide is considered an "experimental" drug in this study. The sponsor is paying for this study to be completed.

IRB: H-51389




Back to topback-to-top